Stocks · News reference
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Common StockPreferred StockDebt SecuritiesWarrantsUnitsand up to 34,449,749 Shares of Common Stock Issuable Upon Exercise ofWarrants and Pre-Funded Warrants Offered, from time to time, by OpusGenetics, Inc.
Read original at benzingaOpus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the
Read original at benzingaFiled: 2026-08-06 AccNo: 0001628280-26-053824 Size: 248 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar